CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Baudax Bio, Inc. - BXRX CFD

1.5750
9.72%
  • Summary
  • Historical Data
  • Events
  • Ownership
Trading Conditions
Spread 0.0400
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024068%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.001846%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.7445
Open* 1.6249
1-Year Change* -4.42%
Day's Range* 1.565 - 1.6447
52 wk Range N/A
Average Volume (10 days) N/A
Average Volume (3 months) N/A
Market Cap N/A
P/E Ratio N/A
Shares Outstanding N/A
Revenue N/A
EPS N/A
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2023 1.7445 -0.2592 -12.94% 2.0037 2.0435 1.5550
Mar 27, 2023 1.9239 0.2093 12.21% 1.7146 2.0535 1.5550
Mar 24, 2023 1.5351 0.0399 2.67% 1.4952 1.6348 1.4852
Mar 23, 2023 1.5251 -0.0200 -1.29% 1.5451 1.5451 1.4852
Mar 22, 2023 1.5451 0.0001 0.01% 1.5450 1.6348 1.5450
Mar 21, 2023 1.5650 -0.0199 -1.26% 1.5849 1.6647 1.5450
Mar 20, 2023 1.5850 -0.1394 -8.08% 1.7244 1.7943 1.5450
Mar 17, 2023 1.7444 0.0100 0.58% 1.7344 1.8641 1.5251
Mar 16, 2023 1.8840 0.5483 41.05% 1.3357 2.1233 1.3357
Mar 15, 2023 1.3058 -0.0598 -4.38% 1.3656 1.3656 1.2360
Mar 14, 2023 1.3557 0.0200 1.50% 1.3357 1.4055 1.3157
Mar 13, 2023 1.3257 -0.0200 -1.49% 1.3457 1.3756 1.2858
Mar 10, 2023 1.3257 -0.1794 -11.92% 1.5051 1.5052 1.2659
Mar 9, 2023 1.5550 -0.1296 -7.69% 1.6846 1.6846 1.5251
Mar 8, 2023 1.6747 -0.0099 -0.59% 1.6846 1.7245 1.6646
Mar 7, 2023 1.7046 -0.0298 -1.72% 1.7344 1.7644 1.6447
Mar 6, 2023 1.7245 -0.0100 -0.58% 1.7345 1.7345 1.6048
Mar 3, 2023 1.7544 -0.0298 -1.67% 1.7842 1.8840 1.7543
Mar 2, 2023 1.8142 -0.1496 -7.62% 1.9638 1.9738 1.7942
Mar 1, 2023 1.9837 -0.1994 -9.13% 2.1831 2.1831 1.9438

Baudax Bio, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events

Start a global, multi-asset portfolio with an award-winning platform

Trade now Desktop

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Baudax Bio, Inc. Company profile

About Baudax Bio Inc

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The Company is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Baudax Bio Inc revenues increased from $493K to $1.1M. Net loss applicable to common stockholders decreased 71% to $22.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Fair Value Adjustments on Other Assets decrease from $2.2M (expense) to $33.3M (income).

People also watch

Oil - Crude

73.40 Price
-0.610% 1D Chg, %
Long position overnight fee -0.0162%
Short position overnight fee -0.0057%
Overnight fee time 21:00 (UTC)
Spread 0.03

BTC/USD

28,349.55 Price
+3.780% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 66.00

US100

12,791.50 Price
+1.400% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

1,965.34 Price
-0.460% 1D Chg, %
Long position overnight fee -0.0087%
Short position overnight fee 0.0005%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading